Free Practice Questions for Saudi Fellowship Adult Nephrology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Saudi Board Specialty Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Sample Saudi Fellowship Adult Nephrology Practice Questions

Try these sample questions to review concepts for the Saudi Fellowship Adult Nephrology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 54-year-old man with newly diagnosed end-stage kidney disease secondary to diabetic nephropathy initiates his first hemodialysis session. His baseline blood urea nitrogen (BUN) is 164 mg/dL (58.5 mmol/L) and serum creatinine is 11.2 mg/dL. Two hours into a high-efficiency dialysis session with a blood flow rate of 350 mL/min, he develops severe headache, nausea, restlessness, and a generalized tonic-clonic seizure. What is the primary underlying pathophysiology of this acute complication?

A.Acute hypocalcemia induced by excessive bicarbonate uptake from the dialysate bath

B.Rapid urea removal creates a reverse osmotic gradient and cerebral oedema

C.Hypoperfusion and cerebral ischemia secondary to unmonitored intradialytic hypotension

D.Acute aluminum neurotoxicity precipitated by contaminated reverse-osmosis dialysate water

Explanation: Dialysis disequilibrium syndrome (DDS) occurs primarily during initial hemodialysis in patients with severe, chronic azotemia (BUN > 100–150 mg/dL). Rapid clearance of urea from the intravascular space creates a transient blood-brain urea gradient ('reverse urea effect') because urea transport across the blood-brain barrier via UT-B channels is rate-limited. Water shifts down the osmotic gradient into brain astrocytes, leading to acute intracellular cerebral edema, elevated intracranial pressure, headache, nausea, and seizures. DDS is prevented by limiting urea clearance during initial sessions (short duration of 2 hours, low blood flow rate of 150–200 mL/min, and concurrent infusion of osmotically active agents such as mannitol).

2A 48-year-old woman underwent creation of a left radiocephalic arteriovenous fistula (AVF) 8 weeks ago. On physical examination, the fistula has a weak, high-pitched systolic-only bruit, a faint thrill palpable only directly over the anastomosis, and a cephalic vein that measures 3.5 mm in diameter with a depth of 7 mm on duplex ultrasonography. The measured access blood flow (Qa) is 310 mL/min. Which of the following is the most appropriate management according to KDOQI vascular access guidelines?

A.Recommendation of daily isometric forearm handgrip exercise for an additional 8 weeks without imaging

B.Immediate placement of a tunneled cuffed internal jugular hemodialysis catheter and abandonment of the AVF

C.Immediate cannulation with 17-gauge needles using a low blood flow rate of 200 mL/min

D.Fistulogram with endovascular treatment of juxta-anastomotic stenosis

Explanation: According to the KDOQI vascular access guidelines, an AVF is considered mature and ready for cannulation when it meets the 'Rule of 6s': blood flow > 600 mL/min, vein diameter >= 6 mm, depth <= 6 mm from the skin surface, and a straight cannulation segment >= 6 cm, typically by 6 to 8 weeks post-surgery. This patient's AVF has failed to mature (diameter 3.5 mm, flow 310 mL/min, depth 7 mm) and demonstrates abnormal physical findings (high-pitched systolic-only bruit indicating inflow or juxta-anastomotic stenosis). Diagnostic fistulogram is indicated to detect and treat juxta-anastomotic stenosis (the most common cause of non-maturation, accounting for > 70% of cases) or coil large accessory/collateral veins that steal flow.

3Which of the following membrane transport characteristics distinguishes online hemodiafiltration (HDF) from conventional high-flux hemodialysis?

A.Exclusive reliance on diffusive solute flux driven by higher dialysate-to-blood countercurrent concentration gradients

B.Added convective transport, clearing middle- and large-molecule solutes

C.Use of low-ultrafiltration coefficient cellulose membranes to prevent albumin loss

D.Substantially lower transmembrane pressure gradients to eliminate internal filtration

Explanation: Online hemodiafiltration (HDF) combines diffusion with high-volume convection. While conventional hemodialysis relies predominantly on diffusive clearance (which efficiently removes small, water-soluble solutes like urea but declines rapidly for molecules > 500 Da), convective clearance drags solutes across a semipermeable membrane via solvent drag alongside high ultrafiltration rates (typically > 23 L of substitution fluid per session in post-dilution mode). This dramatically enhances the clearance of middle molecules (500 to 40,000 Da) such as beta-2 microglobulin, free light chains, and inflammatory cytokines, conferring survival benefits shown in the CONVINCE trial.

4According to the ISO 23500 and AAMI standards for hemodialysis water quality, what are the maximum allowable limits for total viable microbial count and endotoxin concentration in ultrapure dialysate?

A.Microbial count < 500 CFU/mL and endotoxin < 5.0 EU/mL

B.Microbial count < 100 CFU/mL and endotoxin < 0.25 EU/mL

C.Microbial count < 200 CFU/mL and endotoxin < 2.0 EU/mL

D.Microbial count < 0.1 CFU/mL and endotoxin < 0.03 EU/mL

Explanation: International standards (ISO 23500-3 / AAMI) strictly define the microbiological purity of water and dialysate for hemodialysis. Standard dialysate allows a total viable bacterial count < 100 CFU/mL and endotoxin < 0.25 EU/mL. In contrast, ultrapure dialysate (essential for online hemodiafiltration and recommended to suppress chronic microinflammation) requires a microbial count < 0.1 CFU/mL and an endotoxin concentration < 0.03 EU/mL, achieved using point-of-use ultrafilters (polysulfone endotoxin-retentive filters).

5A 66-year-old diabetic man with a left brachiocephalic AVF presents with severe left hand pain, numbness, and coldness that worsens significantly during hemodialysis sessions. Physical examination reveals cool digits, delayed capillary refill (> 4 seconds), absent radial pulse that reappears when the fistula is manually compressed, and early ischemic ulceration at the tip of the second digit. Digital brachial index (DBI) is 0.38 at rest and drops to 0.22 during dialysis. What is the most definitive surgical intervention for this condition?

A.Distal Revascularization and Interval Ligation (DRIL) procedure

B.Endovascular balloon angioplasty of the cephalic arch

C.Immediate permanent surgical ligation of the arteriovenous fistula without revascularization

D.Radial artery embolization distal to the anastomosis

Explanation: This patient has severe Dialysis Access Steal Syndrome (DASS, Stage IV with tissue loss and digital gangrene). DASS occurs when low-resistance retrograde arterial flow through the fistula deprives the distal vascular bed of perfusion. The gold standard surgical procedure for high-flow steal in upper-arm fistulas is Distal Revascularization and Interval Ligation (DRIL). DRIL involves ligating the native brachial artery immediately distal to the fistula anastomosis (eliminating the low-resistance retrograde siphon) and creating a bypass graft (usually using saphenous vein) from the brachial artery proximal to the fistula to the native artery distal to the ligation, thereby preserving fistula patency while restoring antegrade perfusion to the ischemic hand.

6A 62-year-old woman undergoing hemodialysis via a tunneled catheter receives unfractionated heparin for circuit anticoagulation. On day 8, her platelet count has fallen from 240,000/uL to 78,000/uL and the extracorporeal blood circuit repeatedly clots. Her 4Ts score is 7, indicating a high probability of heparin-induced thrombocytopenia (HIT). She has no active bleeding or significant hepatic dysfunction. While confirmatory testing is pending, which management is most appropriate?

A.Switch unfractionated heparin to low-molecular-weight heparin (enoxaparin) 1 mg/kg post-dialysis

B.Discontinue all heparin products (including catheter flushes) and initiate systemic anticoagulation with argatroban

C.Discontinue heparin and transition immediately to regional citrate anticoagulation with no systemic therapy

D.Administer a therapeutic platelet transfusion and continue reduced-dose unfractionated heparin

Explanation: Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder caused by IgG antibodies directed against platelet factor 4 (PF4)-heparin complexes. With a high 4Ts score (>= 6), immediate cessation of all heparin exposures (including heparin locks in catheters) is mandatory. Because HIT is highly thrombogenic (30–50% risk of arterial or venous thrombosis), therapeutic-dose systemic anticoagulation with a non-heparin alternative is required immediately. In end-stage kidney disease on hemodialysis, argatroban is the direct thrombin inhibitor of choice because it undergoes hepatic metabolism and biliary excretion without renal accumulation (monitored by activated partial thromboplastin time [aPTT]).

7Which of the following interventions has been demonstrated to reduce the incidence of intradialytic hypotension and intradialytic myocardial stunning without compromising solute clearance?

A.Cooling the dialysate temperature to 35.0–35.5 °C (isothermic or cooled dialysate)

B.Infusing 500 mL of 0.9% normal saline routinely at the beginning of each session

C.Increasing the ultrafiltration rate above 15 mL/kg/h to shorten treatment duration

D.Switching dialysate buffer from bicarbonate to acetate

Explanation: Intradialytic hypotension (IDH) causes transient myocardial stunning, splanchnic ischemia, and accelerated loss of residual kidney function. Lowering the dialysate temperature (cooled dialysate, typically 0.5–1.0 °C below core body temperature or fixed at 35.0–35.5 °C) stimulates sympathetic vascular tone, promotes venoconstriction, increases venous return and cardiac stroke volume, and stabilizes blood pressure. Landmark trials have confirmed that cool dialysate reduces IDH and protects against recurrent myocardial stunning without compromising Kt/V solute clearance.

8A 68-year-old man on maintenance thrice-weekly hemodialysis presents to the emergency department after a witnessed cardiac arrest occurring 1 hour following his Friday dialysis treatment. Review of his dialysis flowsheets indicates he is dialyzed against a 1.0 mEq/L potassium bath and a 38 mEq/L bicarbonate bath to address recurrent pre-dialysis hyperkalemia (6.2 mEq/L) and acidosis. Post-dialysis serum potassium was 2.8 mEq/L and bicarbonate was 32 mEq/L. Which electrophysiological mechanism best explains this patient's cardiac arrest?

A.Hypercalcemia-induced shortening of the cardiac action potential causing sinoatrial exit block

B.Post-dialytic hypokalaemia with alkalosis prolonging repolarisation

C.Intradialytic hypernatremia triggering diffuse coronary vasospasm

D.Acute hypomagnesemia-mediated complete atrioventricular dissociation

Explanation: The use of a very low potassium dialysate bath (1.0 mEq/L), especially when paired with a high dialysate bicarbonate concentration (>= 35–38 mEq/L), induces rapid transcellular potassium shifts into cells and massive potassium removal. This produces sudden post-dialysis hypokalemia and acute metabolic alkalosis. These combined disturbances hyperpolarize the resting membrane potential, prolong myocardial repolarization (prolonged QTc and Tp-Te intervals), and dramatically elevate the risk of life-threatening ventricular arrhythmias (torsades de pointes, ventricular fibrillation) and sudden cardiac death, which peaks during and immediately following dialysis sessions.

9A 59-year-old woman dialyzing via a right internal jugular tunneled cuffed catheter presents with rigors, fever (38.8 °C), and hypotension 30 minutes into her hemodialysis treatment. Blood cultures drawn simultaneously from the catheter lumens and peripheral veins grow methicillin-resistant Staphylococcus aureus (MRSA). The exit site and subcutaneous tunnel appear clean without erythema or drainage. Transesophageal echocardiography shows no valvular vegetations. What is the most appropriate management regarding the vascular catheter?

A.Immediate removal of the tunneled catheter and initiation of intravenous vancomycin therapy for at least 4 to 6 weeks

B.Retention of the catheter and administration of systemic vancomycin with antibiotic catheter lock solutions for 14 days

C.Exchange of the catheter over a guidewire within 24 hours while continuing systemic vancomycin

D.Temporary cessation of catheter use for 48 hours without catheter removal

Explanation: According to the Infectious Diseases Society of America (IDSA) and KDOQI guidelines, tunneled catheter-related bloodstream infections (CRBSI) caused by virulent organisms—specifically Staphylococcus aureus (both MSSA and MRSA), Pseudomonas aeruginosa, Candida species, or multidrug-resistant pathogens—require immediate catheter removal. S. aureus forms dense biofilms, frequently seeds distant sites (causing osteomyelitis, epidural abscess, endocarditis), and has an unacceptably high failure rate (> 80%) and recurrence rate if catheter salvage or guidewire exchange is attempted. The patient requires parenteral vancomycin for 4 to 6 weeks (guided by trough levels) and temporary non-cuffed access in a different site until blood cultures clear.

10A 65-year-old woman with end-stage kidney disease on maintenance hemodialysis for 6 years, type 2 diabetes mellitus, and atrial fibrillation managed with warfarin presents with exquisitely painful, violaceous, livedoid plaques with central black eschars on both thighs. Laboratory evaluation reveals: serum calcium 10.4 mg/dL (2.60 mmol/L), phosphate 7.2 mg/dL (2.32 mmol/L), intact PTH 520 pg/mL, and INR 2.8. Plain radiograph of the thighs reveals fine, diffuse, reticular calcification of small subcutaneous arteries. Which of the following is the most appropriate multi-interventional therapeutic strategy?

A.Increase warfarin dosage to achieve an INR of 3.0–3.5 and add calcium carbonate phosphate binders

B.Discontinue warfarin, optimize dialytic phosphate clearance with non-calcium binders, and initiate intravenous sodium thiosulfate

C.Perform urgent deep surgical debridement of all painful subcutaneous plaques and administer high-dose calcitriol

D.Administer hyperbaric oxygen therapy as monotherapy and discontinue all dialysis sessions temporarily

Explanation: This patient presents with calcific uremic arteriolopathy (calciphylaxis), a life-threatening syndrome characterized by calcification of the tunica media of subcutaneous arterioles leading to endovascular fibrosis, thrombosis, and ischemic tissue necrosis. Major risk factors include ESRD, diabetes, hyperphosphatemia, elevated calcium-phosphate product, and warfarin therapy (which inhibits matrix Gla protein, a potent endogenous inhibitor of vascular calcification). Management requires a multi-modal strategy: immediate discontinuation of warfarin (replacing with an alternative non-vitamin K anticoagulant if indicated), rigorous normalization of calcium and phosphate using non-calcium-based binders (e.g., sevelamer), lowering dialysate calcium, and initiating intravenous sodium thiosulfate (25 g infused during the last 30–60 minutes of each HD session), which acts as an antioxidant, vasodilator, and calcium-chelating agent.

About the Saudi Fellowship Adult Nephrology Exam

Independent practice question bank by OpenExamPrep for fellows preparing for the Saudi Fellowship Final Written Examination in Adult Nephrology, administered by the Saudi Commission for Health Specialties (SCFHS). This practice resource covers kidney transplantation, hemodialysis, peritoneal dialysis, glomerular and vascular diseases, chronic kidney disease, acute kidney injury, hypertension, tubulointerstitial disorders, acid-base and electrolyte balance, pregnancy-related nephrology, and onco-nephrology. Note: This question bank is an independent English-language MCQ study adaptation for the final written examination and does not simulate the separate mandatory clinical/OSCE and structured oral examination required for sub-specialty certification. OpenExamPrep is not affiliated with or endorsed by SCFHS.

Exam sponsor: Saudi Commission for Health Specialties (SCFHS). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

One paper of 80–120 single-best-answer MCQs. Up to 10% additional unscored items may be added. Duration is not stated in the written blueprint.

Time Limit

Not published by SCFHS

Passing Score

70% (lowered to minimum 65% if pass rate under 70%)

Exam / Certification Fees

Not published by SCFHS

Exam sponsor website

Reported exam pass rate: Not published by SCFHS. SCFHS publishes no candidate pass rate. The blueprint instead sets the passing score at 70% and, if fewer than 70% of candidates pass before final approval, lowers that score one mark at a time until a 70% pass rate is reached or the score reaches 65%, whichever comes first; it is never lowered below 65%. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

14%

Kidney Transplantation

Pre-transplant immunology, donor evaluation, immunosuppressive pharmacology, allograft rejection (TCMR and ABMR), opportunistic infections, and post-transplant complications.

12%

Haemodialysis

Vascular access management, dialysis kinetics, membrane biocompatibility, water treatment standards, anticoagulation, and intradialytic acute and chronic complications.

12%

Glomerular and Vascular

Primary and secondary glomerulopathies, nephrotic and nephritic syndromes, ANCA-associated vasculitis, anti-GBM disease, lupus nephritis, and thrombotic microangiopathies.

10%

Peritoneal Dialysis

Peritoneal membrane physiology and transport kinetics (PET), PD modalities, peritonitis diagnosis and management, catheter exit-site infections, and non-infectious complications.

10%

Chronic Kidney Disease

Staging and risk stratification, progression retardation, CKD-MBD, renal osteodystrophy, anemia management, metabolic acidosis, and renal replacement preparation.

10%

Acute Kidney Injury

KDIGO classification, pre-renal azotemia vs ATN, pigment nephropathy, contrast-associated AKI, cardiorenal/hepatorenal syndromes, CRRT principles, and acute interstitial nephritis.

Hypertension

Primary aldosteronism, renovascular hypertension, pheochromocytoma, hypertensive emergencies, resistant hypertension, and blood pressure targets in kidney disease.

Tubulointerstitial, Cystic and Nephrolithiasis

Autosomal dominant and recessive polycystic kidney disease, tubulointerstitial nephritis, medullary cystic disorders, and nephrolithiasis metabolic evaluation and prevention.

Acid-Base

High anion gap and non-gap metabolic acidosis, renal tubular acidoses (Types 1, 2, and 4), saline-responsive vs resistant metabolic alkalosis, and mixed acid-base disorders.

Fluid and Electrolytes

Dysnatremias (hypo- and hypernatremia physiology and correction rates), potassium disorders (emergency hyperkalemia, hypokalemia), and calcium, phosphate, and magnesium disturbances.

Pregnancy and Kidney Disease

Renal physiological adaptations in pregnancy, preeclampsia vs chronic kidney disease, lupus nephritis in pregnancy, fetal-safe antihypertensives, and dialysis management during pregnancy.

Onco-Nephrology and Pharmacology

Immune checkpoint inhibitor-induced AKI, VEGF-inhibitor nephrotoxicity, chemotherapy-induced tubular and glomerular injuries, monoclonal gammopathy of renal significance (MGRS), and drug clearance adjustments.

Preparing for the Saudi Fellowship Adult Nephrology Exam

What You Need to Know

Passing score: 70% (lowered to minimum 65% if pass rate under 70%)
Assessment: One paper of 80–120 single-best-answer MCQs. Up to 10% additional unscored items may be added. Duration is not stated in the written blueprint.
Time limit: Not published by SCFHS
Exam / certification fees: Not published by SCFHS Official sources

Using Our Practice Resources

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Saudi Fellowship Adult Nephrology: Suggested Study Strategy

1Prioritize high-yield blueprint domains: Kidney Transplantation (14%), Haemodialysis (12%), and Glomerular and Vascular Diseases (12%) account for nearly 40% of all exam questions.

2Review KDIGO clinical practice guidelines for glomerulonephritis, CKD evaluation and management, AKI, and kidney transplant recipient care.

3Master diagnostic immunological parameters in transplantation, including donor-specific antibodies (DSA), C4d complement staining, Banff biopsy criteria, and opportunistic infection protocols (CMV, BKV, PJP).

4Thoroughly understand dialytic kinetics, vascular access surveillance, water purification standards (AAMI/ISO), and peritoneal equilibration test (PET) classification and prescription optimization.

Frequently Asked Questions

What is the format of the Saudi Fellowship Adult Nephrology Final Written Examination?

One paper of 80–120 single-best-answer MCQs. Up to 10% additional unscored items may be added. Duration is not stated in the written blueprint.

What is the passing score for the Adult Nephrology fellowship written examination?

The passing benchmark is set at 70%. If the overall candidate pass rate falls below 70%, the passing score is adjusted downward one mark at a time until reaching a 70% candidate pass rate, with an absolute minimum floor of 65%.

Does this question bank include the clinical OSCE examination?

This bank is an independent English-language MCQ study adaptation for the written examination. It does not simulate or replace the separate mandatory final clinical/practical assessment. Consult the specialty clinical blueprint for its station formats and any structured oral or OSCE components.

How does this exam differ from the SCFHS Nephrology classification exam?

The Saudi Fellowship Final Written Examination in Adult Nephrology is the terminal specialty qualification for sub-specialty fellows completing accredited advanced training. The SCFHS Nephrology classification exam is an evaluation used for credentialing international medical graduates and specialists entering practice in Saudi Arabia.

Who administers the Saudi Fellowship in Adult Nephrology?

The examination and fellowship certification are administered by the Saudi Commission for Health Specialties (SCFHS). OpenExamPrep is an independent educational platform and is not affiliated with or endorsed by SCFHS.

Free Practice Questions for Saudi Fellowship Adult Nephrology

Explore More Saudi Board Specialty Exams

Saudi Board Anesthesia Final Written Exam (SCFHS)

Saudi Board Emergency Medicine Final Written Exam (SCFHS)

Saudi Board Dermatology Final Written Exam (SCFHS)

Saudi Board Orthopedic Surgery Final Written Exam (SCFHS)

Saudi Board Diagnostic Radiology Final Written Exam (SCFHS)

Saudi Board Family Medicine Final Written Exam (SCFHS)